Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BD Diagnostics, a segment of Becton, Dickinson and Company, has announced the CE marking of the BD GeneOhm VanR assay for the rapid detection of vanA and vanB genes, which are associated with vancomycin-resistant Enterococci.
Subscribe to our email newsletter
The BD GeneOhm VanR assay is a qualitative in vitro polymerase chain reaction test for the detection of vancomycin-resistant genes directly from perianal and rectal swabs. As the first CE-marked molecular assay to directly test clinical specimens, the test is said to allow hospitals and reference laboratories to identify patients colonized with the resistant organisms associated with vancomycin-resistant Enterococci (VRE) in as little as two hours.
The new test is also expected to help enable earlier implementation of infection control measures to prevent VRE transmission and infection, leading to decreased length of stay and reduced healthcare costs. BD will immediately begin commercializing this important new assay throughout Europe.
Jamie Condie, vice president/general manager, BD Diagnostics, said: “With the addition of the BD GeneOhm VanR assay, BD continues to demonstrate its commitment to improving patient care and preventing healthcare-associated infections (HAIs). Our existing HAIs-related molecular menu includes assays for the rapid detection of methicillin-resistant and methicillin-susceptible Staphylococcus aureus.”